Management is pivoting toward a global oncology enterprise, transitioning from a discovery-focused biotech to a commercial-stage organization with 8 ongoing or planned Phase III trials. The 'virtuous cycle' of innovation is driven by the tri-complex platform, which has enabled the rapid advancement of four clinical-stage RAS(ON) inhibitors targeting major oncogenic drivers. Pancreatic cancer remains the primary strategic focus, with daraxonrasib showing an unprecedented clinical profile that earned FD ...